CXCR4 and ovarian cancer: The blockade of the SDF-1—CXCR4 interaction, combined with anti-programmed death 1 (PD-1)-based immunotherapy, results in a higher M1/M2 ratio, which is associated with better clinical outcomes in patients with ovarian cancer [242].